ARIES

Peak, India
Peak, India

Time filter

Source Type

News Article | June 28, 2017
Site: www.prnewswire.co.uk

The CDC reports that norovirus is estimated to be the most common cause of acute gastroenteritis worldwide, and each year, norovirus causes over 200,000 deaths and a global economic burden of more than $60 billion.1 As the fifth CE-marked assay for use on Luminex's ARIES® Systems, the Norovirus Assay adds to a growing menu of tests for the ARIES® platform. The system is designed to run in multiple laboratory shifts and allows labs to simultaneously run both IVD and LDT assays in a sample to answer format when using a Universal Assay Protocol. "We are very excited to add the simple and cost-effective Norovirus Assay to our expanding menu of assays for ARIES®," said Thomas Pracht, managing director of Luminex Europe. "The ARIES® Norovirus Assay offers excellent performance for high confidence in results and reduced hands-on time compared to other molecular assays. Further, by enabling rapid and accurate diagnosis even outside office hours, the assay can expedite appropriate infection control measures." ARIES® Systems automate all aspects of testing, from sample preparation through analysis, providing answers in less than 2 hours with minimal hands-on time while enabling easy implementation on weekends and night shifts. The ARIES® Norovirus Assay, a real-time polymerase chain reaction (PCR)-based qualitative in vitro diagnostic test, is part of Luminex's comprehensive gastroenterological testing menu that also includes the xTAG® Gastrointestinal Pathogen Panel (GPP), VERIGENE® Enteric Pathogens Test (EP), and the ARIES® C. difficile Assay (RUO). The ARIES® Norovirus Assay is intended to aid in the diagnosis of norovirus infections when used in conjunction with clinical evaluation, laboratory findings, and epidemiological information. The assay also aids in the detection and identification of norovirus infections in the context of outbreaks. For more information, please visit www.luminexcorp.com/norovirus ARIES® Systems are sample to answer molecular diagnostic systems designed to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into today's lean laboratory environment. ARIES® uses internal barcode scanning and other advanced features to minimize operator errors. Independent modules support from one to six cassettes, allowing for both STAT and batch testing of IVD assays and laboratory developed tests (LDTs) with MultiCode® Reagents when using a universal assay protocol. An integrated touchscreen PC eliminates the need for a separate computer, standalone keyboard, and mouse, maximizing valuable bench space. To learn more or request a demo, please visit: http://www.luminexcorp.com/ARIES At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health.  We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. We accelerate reliable answers while simplifying complexity and deliver certainty with a seamless experience. To learn more about Luminex, please visit us at www.luminexcorp.com. Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding the available market and customer acceptance for ARIES®, future revenue growth anticipated for ARIES®, and the development, testing and regulatory approval progress of our pipeline products, including ARIES® related assays. The words "believe", "expect", "intend", "anticipates", "confident", "will", "could", "should",  and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, our ability to launch products on time, the timing of regulatory approvals, the outcome of clinical trials as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


News Article | November 17, 2016
Site: www.prnewswire.co.uk

Journal of Clinical Virology Publication Demonstrates Effectiveness and Ease of Use for Routine Testing AUSTIN, Texas, Nov. 17, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the internationally renowned Department of Viroscience at Erasmus Medical Center in Rotterdam, The Netherlands, has evaluated the ARIES® System and Flu A/B & RSV CE-IVD Assay for clinical testing in a recently published study. Erasmus MC is a consultation center for the World Health Organization on viral infections, as well as serving as the National Reference Center for Influenza and Emerging Infections in The Netherlands. In the study, the ARIES® platform and Flu A/B & RSV Assay showed a high clinical specificity and sensitivity, comparable to laboratory developed RT-PCR assays, and better than those of established assays such as immunochromatographic tests and direct immunofluorescence assays. Ease of use was found to be comparable to other rapid molecular test platforms. The ARIES® platform is unique in that it can also run in-house developed real-time assays with generic ARIES® cassettes. "We are proud that after thorough evaluation, ARIES has been found to be effective and easy to use by one of the world's leading medical centers for clinical virology," said Thomas Pracht, Managing Director, EMEIA, at Luminex Corporation. "The Erasmus study demonstrates the quality and performance of the ARIES® platform and the value of the system for molecular diagnostic labs that want to perform 'out of sync' MDx testing — in other words, outside of office hours testing or stat testing during office hours in between runs. The study also underlines the importance of 'point of impact' tests, where results have an immediate impact on patient care and clinical decision making, even outside normal office hours." Read the complete study, "Performance evaluation of a rapid molecular diagnostic, MultiCode based, sample-to-answer assay for the simultaneous detection of Influenza A, B and respiratory syncytial viruses," published in the Journal of Clinical Virology, December 2016, Volume 85, Pages 65–70. About Luminex Corporation At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. We accelerate reliable answers while simplifying complexity, and deliver certainty with a seamless experience. To learn more about Luminex, please visit us at luminexcorp.com. Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding the development and testing progress of our pipeline products, and the regulatory approvals thereof. The words "believe", "expect", "intend", "anticipates", "confident", "will", "could", "should", and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, our ability to launch products on time, the timing of regulatory approvals, the outcome of clinical trials as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


News Article | November 17, 2016
Site: www.prnewswire.co.uk

Publikation im Journal of Clinical Virology demonstriert Effektivität und einfache Handhabung für Routinetests AUSTIN, Texas, 17. November 2016 /PRNewswire/ -- Die Luminex Corporation (NASDAQ: LMNX) gab heute bekannt, dass die international renommierte Abteilung für Virologie im Erasmus Medical Center in Rotterdam, Niederlande, das ARIES® System und Flu A/B & RSV CE-IVD Assay für klinische Tests in einer kürzlich veröffentlichten Studie evaluiert hat. Das Erasmus MC ist ein Konsultationszentrum zu viralen Infektionen für die Weltgesundheitsorganisation und dient ebenfalls in den Niederlanden als nationales Referenzzentrum für Influenza und aufkommende Infektionen. In der Studie zeigten die ARIES® Plattform und das Flu A/B & RSV Assay eine hohe klinische Spezifizität und Sensitivität, die mit laborentwickelten RT-PCR Assays vergleichbar sind, sowie bessere Ergebnisse in diesem Zusammenhang als jene von etablierten Assays, wie z. B. immunchromatographische Tests und direkte Immunfluoreszenz-Tests. Die Anwenderfreundlichkeit ist laut Studie mit anderen schnellen molekularen Testplattformen gleichzusetzen. Die ARIES® Plattform ist insofern einzigartig, da man mit ihr ebenfalls intern entwickelte Assays in Echtzeit mit generischen ARIES® Kassetten durchführen kann. „Wir sind sehr stolz, dass eines der führenden medizinischen Zentren für klinische Virologie nach einer sorgfältigen Beurteilung die Effektivität und leichte Handhabung von ARIES festgestellt hat", sagte Thomas Pracht, Managing Director für EMEIA bei der Luminex Corporation. „Die Erasmus-Studie zeigt die Qualität und Leistung der ARIES® Plattform und den Nutzen des Systems für Molekulardiagnose-Labore, die MDx-Testverfahren „außerhalb des Takts" durchführen wollen – in anderen Worten, außerhalb der offiziellen Dienstzeiten für Tests oder beispielsweise Statistiktests zwischen den Testläufen während der offiziellen Dienstzeiten im Labor. Die Studie unterstreicht ebenfalls die Bedeutung der Tests mit Direktauswirkung, bei denen die Resultate zu unmittelbaren Folgen für die Patientenbehandlung und die klinische Entscheidungsfindung führen – selbst außerhalb der normalen Dienstzeiten." Lesen Sie die komplette Studie „Performance evaluation of a rapid molecular diagnostic, MultiCode based, sample-to-answer assay for the simultaneous detection of Influenza A, B and respiratory syncytial viruses", veröffentlicht im Journal of Clinical Virology, Dezember 2016, Volume 85, Seiten 65-70. Über die Luminex Corporation Luminex hat sich das Ziel gesetzt, Labore bei der Suche nach zuverlässigen, zeitnahen und umsetzbaren Antworten zu unterstützen, um letztlich zur Förderung der Gesundheit beizutragen. Wir bieten ein breites Spektrum von Lösungen, die in verschiedenen Märkten eingesetzt werden können, unter anderem in den Bereichen klinische Diagnostik, pharmazeutische Wirkstoffentwicklung, Genom- und Proteomikforschung, biologische Abwehrforschung und Lebensmittelsicherheit. Unser Unternehmen stellt Antworten schneller bereit, vereinfacht gleichzeitig die Komplexität und verschafft sichere Erkenntnisse auf der Grundlage einer nahtlosen Anwendererfahrung. Weitere Informationen über Luminex erhalten Sie, wenn Sie luminexcorp.com aufrufen. Aussagen in dieser Pressemitteilung, welche die Absichten, Pläne, Überzeugungen, Erwartungen oder Prognosen von Luminex bzw. der Geschäftsführung von Luminex zu zukünftigen Ereignissen ausdrücken, sind sogenannte vorausschauende Aussagen. Zu den vorausschauenden Aussagen in dieser Pressemitteilung gehören Aussagen über die Entwicklung und die Prüfungsfortschritte unserer Pipeline-Produkte sowie über deren regulatorische Zulassung. Begriffe wie „glauben", „erwarten", „beabsichtigen", „prognostizieren", „überzeugt", „werden", „könnten", „sollten" und ähnliche Ausdrücke weisen auf derartige vorausschauende Aussagen im Sinne des Private Securities Litigation Reform Act von 1995 hin und machen sie kenntlich. In diesem Zusammenhang wird ausdrücklich darauf hingewiesen, dass sich die tatsächlichen Ergebnisse oder Leistungen des Unternehmens wesentlich von jenen unterscheiden könnten, die in solchen vorausschauenden Aussagen prognostiziert werden. Zu den Faktoren, die dazu führen könnten, dass die tatsächlichen Ergebnisse oder Leistungen von Luminex erheblich abweichen, gehören Risiken und Unwägbarkeiten u. a. im Zusammenhang mit unserer Fähigkeit, Produkte zeitnah auf dem Markt einzuführen, mit dem zeitlichen Ablauf regulatorischer Zulassungen und dem Ergebnis klinischer Studien ebenso wie die im Abschnitt „Risikofaktoren" in den von Luminex bei der Securities and Exchange Commission auf den Formularen 10-K und 10-Q eingereichten und erörterten Risiken. Die hier enthaltenen vorausschauenden Aussagen geben die Einschätzung von Luminex zum Zeitpunkt der Veröffentlichung dieser Pressemitteilung wieder und Luminex lehnt ausdrückliche jede Absicht, Verpflichtung oder Zusicherung ab, öffentlich Aktualisierungen oder Berichtigungen an vorausschauenden Aussagen vorzunehmen, um Änderungen der Erwartungen von Luminex in diesem Zusammenhang oder Änderungen aufgrund von Ereignissen, Bedingungen oder Umständen, auf denen vorausschauenden Aussagen basieren, widerzuspiegeln.


Le Journal of Clinical Virology démontre l'efficacité et la facilité d'utilisation pour les tests de routine AUSTIN, Texas, 17 novembre 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ : LMNX) a annoncé aujourd'hui que le mondialement renommé Département de viroscience du centre médical Erasme à Rotterdam, aux Pays-Bas, a évalué le système ARIES® et le kit CE-DIV de dépistage de la grippe A/B et du RSV dans une étude publiée récemment. Le centre médical Erasme est un centre de consultation sur les infections virales recommandé par l'Organisation mondiale de la Santé. Il sert aussi de Centre national de référence sur la grippe et les infections émergentes aux Pays-Bas. Selon l'étude, la plateforme ARIES® et le kit de dépistage de la grippe A/B et du RSV ont démontré une spécificité et une sensibilité clinique élevées, comparables aux tests RT-PCR développés en laboratoire. Ils ont affiché de meilleures performances que les tests immunochromatographiques et les essais d'immunofluorescence directe. Leur facilité d'utilisation a été jugée comparable à celle d'autres plateformes de tests moléculaires rapides. La plateforme ARIES® est unique en ce qu'elle peut également gérer en temps réel des essais développés en interne grâce à des cassettes ARIES® génériques. « Nous sommes fiers qu'après une évaluation approfondie, l'efficacité et la facilité d'utilisation d'ARIES aient été démontrées par l'un des centres médicaux de virologie clinique les plus importants du monde », a déclaré Thomas Pracht, directeur général, EMEIA, chez Luminex Corporation. « L'étude Erasme démontre la qualité et la performance de la plateforme ARIES® et la valeur du système pour les laboratoires de diagnostic moléculaire qui veulent effectuer des essais médicaux « hors horaire » ou, en d'autres termes, en dehors des plages horaires réservées aux tests. L'étude souligne également l'importance du « point d'impact » des tests, quand les résultats ont un impact immédiat sur les soins thérapeutiques et les prises de décision clinique, même en dehors des heures de bureau habituelles ». Voici les références de l'étude complète : « Performance evaluation of a rapid molecular diagnostic, MultiCode based, sample-to-answer assay for the simultaneous detection of Influenza A, B and respiratory syncytial viruses », publiée dans le Journal of Clinical Virology, décembre 2016, Volume 85, Pages 65–70. À propos de Luminex Corporation Chez Luminex, notre mission consiste à permettre aux laboratoires d'obtenir, en temps opportun, des réponses fiables et décisives, pour faire progresser la santé.  Nous offrons une large gamme de solutions applicables dans divers marchés, dont le diagnostic clinique, la mise au point de médicaments pharmaceutiques, la recherche biomédicale, la recherche en génomique et en protéomique, la recherche de biodéfense et la sécurité alimentaire. Nous accélérons des réponses fiables tout en simplifiant la complexité, et en offrant la sécurité avec une expérience transparente. Pour en savoir plus sur Luminex, veuillez consulter le site luminexcorp.com. Les énoncés contenus dans le présent communiqué de presse qui expriment les intentions, les projets, les convictions, les attentes ou les prédictions d'événements futurs de Luminex ou de sa direction constituent des énoncés prospectifs. Parmi les énoncés prospectifs du présent communiqué figurent des déclarations concernant les processus de mise au point et de tests de nos produits en cours et de leurs approbations réglementaires. Les termes « pense », « espère », « a l'intention de », « anticipe », « est certain de », « fera », « pourrait », « devrait » et des expressions comparables visent à identifier de tels énoncés prospectifs au sens de la Private Securities Litigation Reform Act de 1995. Il est important de noter que les résultats ou les performances réels de la Société peuvent différer sensiblement de ceux qui sont anticipés dans ces énoncés prospectifs. Parmi les facteurs susceptibles d'engendrer une différence significative avec les résultats et les performances réels de Luminex, figurent les risques et les incertitudes liés entre autres à notre capacité à lancer nos produits en temps voulu, au calendrier des approbations réglementaires, à l'issue des essais cliniques ainsi qu'aux risques évoqués dans la rubrique « Risk Factors » dans les rapports de Luminex sur formulaires 10-K et 10-Q déposés auprès de la Securities and Exchange Commission. Les énoncés prospectifs contenus dans le présent communiqué de presse forment le jugement de Luminex à la date dudit communiqué de presse, et Luminex rejette expressément toute intention, obligation ou engagement consistant à publier les mises à jour ou révisions de tout énoncé prospectif afin de refléter tout changement dans les prévisions de Luminex à cet égard, ou toute modification des événements, conditions ou circonstances sur lesquels s'appuient ces énoncés.


(PRLEAP.COM) NEW YORK – January 25, 2017 – SpeedNews Conferences , the premier conference organizer in the global aerospace and defense industry, will bring two of its signature events to the Beverly Wilshire in Beverly Hills, CA in Spring 2017, offering aviation industry leaders the opportunity to hear best practices, network and share information.The SpeedNews 7th Annual Aerospace Raw Materials & Manufacturers Supply Chain Conference opens this unique event series on March 13, 2017. Designed for leaders in the dynamic global commercial and military aircraft markets, the event will include topics of interest for equipment OEMs, sub-tier manufacturers, material and parts suppliers, supply chain executives, market analysts, and investment bankers. Speakers will address topics including supply chain strategies, demand outlook for aerospace part manufacturers, market and supplier trends, and the impact of new materials challenging traditional material manufacturing. The event is sponsored by Aero Metals Alliance, Accurus Aerospace Corporation, ARIES Manufacturing and Toray Composites (America), Inc. To register, visit http://speednews.com/aerospace-raw-materials-and-manufacturers-supply-chain-conference/registration The SpeedNews 31st Annual Commercial Aviation Industry Suppliers Conference will take place on March 13-15, 2017, uniting equipment manufacturers, material suppliers, aviation analysts, financial institutions, and marketing executives. During the event, aircraft and engine manufacturers will present status reports on product strategies, and market developments. Industry experts will discuss production and delivery forecasts, and review the current economic status of the industry. Supply chain management, maintenance and subcontractor issues will also be addressed. The event is sponsored by Accurus Aerospace, CIRCOR Aerospace, Moss-Adams LLP, Valence Surface Technologies, CFM International, Exova Aerospace, CIT, Precision Castparts Corporation, and State of Alabama. To register, visit http://speednews.com/commercial-aviation-industry-suppliers-conference The SpeedNews 31st Annual Commercial Aviation Industry Suppliers Conference will mark the presentation of the Third Annual Gilbert W. Speed Award on March 14, recognizing an individual who demonstrates outstanding leadership and collaboration across the global aerospace and defense supply chain. The award honors the legacy of the man who founded SpeedNews, the aviation industry's newsletter of record, in 1979 and established its annual suppliers Conference in 1987. David P. Storch, Chairman & CEO of AAR, was the award's inaugural winner in 2015. Scott A. Smith, President of AMI Metals, received the award in 2016. Nominations are being accepted through February 10, 2017 at http://lister.speednews.com/gws/ Speakers across the two Conferences include representatives from:For information about Conference registration, promotional and advertising opportunities, contact Joanna Speed at +1-424-465-6501 or jspeed@speednews.com . On Twitter, follow @speednewsconf ( https://twitter.com/speednewsconf ). For information about all SpeedNews events, visit http://speednews.com/all/conference ABOUT SPEEDNEWS CONFERENCESSpeedNews Conferences, the leader in global executive events, provides targeted information and professional networking opportunities for senior level aerospace industry leaders, decision makers, financial institutions, economic development organizations, and industry analysts. These Conferences deliver an array of information and data for commercial, defense, business and general aviation, aerospace manufacturing, raw materials, and M&A developments.SpeedNews Conferences offer an unmatched depth of market data and innovative ways to present organizations' materials. Meet with distinguished experts in the aerospace industry, learn about current trends, new products and developments, hear forecasts, and network with customers and peers. From aircraft and engine manufacturing to current financial reports and data, you will walk away with timely, crucial knowledge from these experts to help guide your business plans.ABOUT AVIATION WEEK NETWORKThe Aviation Week Network is the largest multimedia information and services provider for the global aviation, aerospace and defense industries that has a database of 1.2 million professionals around the world. Industry professionals rely on Aviation Week for analysis, marketing and intelligence. Customers include the world's leading manufacturers, suppliers, airlines, business aviation operators, militaries, governments and other organizations that serve this global market. The product portfolio includes Aviation Week & Space Technology, AC-U-KWIK, Aircraft Blue Book, Airportdata.com, Air Charter Guide, Air Transport World, AviationWeek.com, Aviation Week Intelligence Network, Business & Commercial Aviation, ShowNews, SpeedNews, Fleet and MRO forecasts, global maintenance, repair and overhaul (MRO) tradeshows and aerospace & defense conferences.ABOUT INFORMASpeedNews is part of Informa, the international business intelligence, academic publishing, knowledge and events group. Informa serves commercial, professional and academic communities, helping them connect and learn, also creating and providing access to content and intelligence that helps people and businesses work smarter and make better decisions faster.Informa has over 7,500 colleagues in more than 20 countries and a presence in all major geographies. It is listed on the London Stock Exchange and is a member of the FTSE 100.


News Article | April 14, 2016
Site: phys.org

"We are really going at this problem from every possible angle," Facebook co-founder and chief Mark Zuckerberg said of efforts by the social network to make Internet connectivity more widely available around the world. Facebook used its annual developers conference to reveal Terragraph technology that uses low-cost, off-the-shelf components to create antenna-based networks in dense city settings to improve wireless Internet availability. The technology "incorporates attributes and industrial design required for fast, attractive and affordable deployment across cityscapes," Neeraj Choubey and Ali Yazdan Panah of Facebook said in a blog post. "Its reduced interference and ability to operate in non-line-of-sight conditions increases customer reach." Terragraph "nodes" can be mounted outside high-rises or other big buildings and connected to Internet connections inside. Terragraph is being tested at the Facebook campus in Silicon Valley and will soon start a broader trial in the nearby California city of San Jose. A Project ARIES at Facebook has a goal of building a test platform for efficient ust of energy and unused radio spectrum that could provide a way to deliver Internet to communities outside of cities. "We are interested in developing this technology to harness the incredible gains in providing communications to rural communities from city centers," Choubey and Panah said. "The hope with systems such as these is that costly rural infrastructure can be avoided while still providing high-speed connectivity." Facebook stressed that it was not interested in being an Internet service provider, but wanted to show those who do what could be possible. "Moreover, we would like to make this technology open to the wireless communications research and academic community," the blog post said. The leading social network in coming months will launch its first satellite to provide Internet service to sub-Saharan Africa, Zuckerberg said at the conference. Facebook's mission to connect the world has included building solar-powered Aquila drones capable of transmitting data using lasers. "If you had told me 12 years ago that we were going to be building a plane, I would have told you that you are crazy," Zuckerberg said as he showed off a lightweight piece of a drone during a keynote presentation. "Well, here we are." Facebook estimates that more that four billion people don't have access to the Internet for reasons that include access and cost. As part of an often-shared long-range vision of letting people anywhere share whatever they want with anyone using the Internet, Zuckerberg on Wednesday announced the creation of a "Building 8" team devoted to building new hardware products for connecting the world. Facebook hired Regina Dugan away from an Advanced Technology and Projects group at Google to head the new team, according to Zuckerberg. Before joining Google, Dugan was director of the Defense Advanced Research Projects Agency devoted to innovations for the US military. "I'm excited to have Regina apply DARPA-style breakthrough development at the intersection of science and products to our mission," Zuckerberg said. Facebook will devote hundreds of people and invest hundreds of millions of dollars to the effort as it pursues a 10-year roadmap that includes virtual reality, artificial intelligence, and online connectivity, according to Zuckerberg. Explore further: Facebook founder aims to get India online


News Article | November 17, 2016
Site: www.prnewswire.com

AUSTIN, Texas, Nov. 17, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the internationally renowned Department of Viroscience at Erasmus Medical Center in Rotterdam, The Netherlands, has evaluated the ARIES® System and Flu A/B & RSV CE-IVD Assay for...


News Article | December 5, 2016
Site: www.prnewswire.com

AUSTIN, Texas, Dec. 5, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the company was awarded the prestigious R&D 100 Award for its ARIES® Systems at the 54th Annual R&D 100 Awards ceremony in November. The R&D 100 Awards, presented by R&D...


News Article | December 5, 2016
Site: globenewswire.com

In line with ÅF's growth strategy and the ambition to strengthen its global position in the renewable energy sector, ÅF is acquiring the energy division of the Spanish engineering company ARIES Ingeniería y Sistemas. ARIES is an independent engineering company based in Madrid with an energy division offering consulting and engineering services within the renewable sector, focusing on solar power for the global market. ARIES has a solid track record in the development, engineering, construction supervision and operation of solar power plants in over 22 countries. "We are pleased to welcome the energy division of ARIES to ÅF. The acquisition is part of our growth strategy and will strengthen our global position in the renewable energy sector", said Jonas Wiström, President and CEO of ÅF. "The combination of ÅF and the expertise of ARIES in the renewable energy sector will create new business opportunities. The transaction will create added value for clients and employees," said Javier Rojas, President of Aries Ingeniería y Sistemas S.A. "Together with ARIES we will have a strong global offering and comprehensive knowledge of all the required technical, environmental, regulatory and financial aspects to improving the use of renewable energy sources," comments Roberto Gerosa, President of ÅF's International Division. The energy division of ARIES has about 30 employees and annual sales of EUR 5 million. It is consolidated from December 1 2016.. ÅF is an engineering and consulting company for the energy, industrial and infrastructure markets, creating progress for our clients since 1895. By connecting technologies, we provide profitable, innovative and sustainable solutions to shape the future and improve people's lives. Building on our strong base in Europe, our business and clients are found all over the world.


Facebook wishes to connect everybody together through the Internet on a global scale. For it to achieve this feat, the company unveiled during the F8 developers conference on April 13 its new terrestrial connectivity systems, dubbed Terragraph and Project ARIES, to provide speedier and cheaper Internet access across the globe. Terragraph makes use of a 60 GHz and multi-node wireless system aimed in bringing speedy Internet connectivity particularly to areas in which population is dense. The company says the system leverages so-called "commercial off-the-shelf" parts plus the cloud for rigorous data processing for low-cost, high-volume production. Project ARIES (which stands for Antenna Radio Integration for Efficiency in Spectrum), is Facebook's initiative to install antennas to provide connectivity to more than 90 percent of the world's population who are living within 40 kilometers (24 miles) of a city. The company says the project targets to put base stations that have 96 antennas to support 24 streams at 71 bits per second in urban areas to extend connectivity out to rural places. "Facebook's Connectivity Lab is working on a range of new technology solutions to help connect the unconnected and improve the experience of the undeserved," says Facebook in a blog post. "Today, we announced two new terrestrial systems focused on improving the speed, efficiency and quality of Internet connectivity around the world - Terragraph and Project ARIES." Facebook says that it does not intend to build the networks. Rather, it is going rely on carriers and Internet service providers to make these projects successful. The company is determined to push these projects to boost connectivity speed by 10 times and trim down the cost by 10 times. "We don't want to make things just a little bit better," said Facebook's vice president of engineering Jay Parikh during the conference. "We're working on things that will make things 10x faster, 10x cheaper, or both." This recent move from Facebook is seen as part of what Facebook CEO Mark Zuckerberg's calls the company's humanitarian project, to "continue connecting the world." Terragraph, ARIES and Aquila are the company's grand projects to do just that in the next few years. Facebook is presently testing out Terragraph at the company's headquarters in Menlo Park. It says it is gearing up to pilot its program in San Jose, California later this year. © 2016 Tech Times, All rights reserved. Do not reproduce without permission.

Loading ARIES collaborators
Loading ARIES collaborators